Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Koeppen

Showing results (101-110 of 147) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancerSuparna Bonthala Wedam, Jennifer A Low, Sherry X Yang, et al.
NPJ Breast Cancer|July 20, 2017
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant populationTimothy R Wilson, Jianjun Yu, Xuyang Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid TumorsSaoirse O Dolly, Andrew J Wagner, Johanna C Bendell, et al.
Nature|February 5, 2010
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthGeorgia Hatzivassiliou, Kyung Song, Ivana Yen, et al.
Nature Medicine|June 23, 2022
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinomaAndrew X Zhu, Alexander R Abbas, Marina Ruiz de Galarreta, et al.
Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 18, 2016
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human GlioblastomaLaurent Salphati, Bruno Alicke, Timothy P Heffron, et al.
Nature Communications|August 31, 2016
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaJeffrey J Wallin, Johanna C Bendell, Roel Funke, et al.
Nature Communications|April 20, 2022
Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitorsKristin M Zimmerman Savill, Brian B Lee, Jason Oeh, et al.
Cancer Research|November 18, 2008
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateGail D Lewis Phillips, Guangmin Li, Debra L Dugger, et al.
Pageof 15

Showing results (101-110 of 147) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancerSuparna Bonthala Wedam, Jennifer A Low, Sherry X Yang, et al.
NPJ Breast Cancer|July 20, 2017
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant populationTimothy R Wilson, Jianjun Yu, Xuyang Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid TumorsSaoirse O Dolly, Andrew J Wagner, Johanna C Bendell, et al.
Nature|February 5, 2010
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthGeorgia Hatzivassiliou, Kyung Song, Ivana Yen, et al.
Nature Medicine|June 23, 2022
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinomaAndrew X Zhu, Alexander R Abbas, Marina Ruiz de Galarreta, et al.
Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 18, 2016
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human GlioblastomaLaurent Salphati, Bruno Alicke, Timothy P Heffron, et al.
Nature Communications|August 31, 2016
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaJeffrey J Wallin, Johanna C Bendell, Roel Funke, et al.
Nature Communications|April 20, 2022
Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitorsKristin M Zimmerman Savill, Brian B Lee, Jason Oeh, et al.
Cancer Research|November 18, 2008
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateGail D Lewis Phillips, Guangmin Li, Debra L Dugger, et al.
Pageof 15